

This brochure was made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of AVAC and do not necessarily reflect the views of USAID or the United States Government.

As of April 2014
And many other generous individuals from around the world
Becton, Dickinson and Company (BD) ■ Bill & Melinda Gates Foundation ■ Bristol-Myers Squibb ■ Broadway Cares/Equity Fights AIDS ■ The City of New York, Economic Development Corporation ■ Foundation for the National Institutes of Health ■ The Gilead Foundation ■ GlaxoSmithKline ■ Google Inc. ■ Government of Japan ■ The Hearst Foundations ■ Institut Mérieux ■ Irish Aid ■ James B. Pendleton Charitable Trust ■ Ministry of Foreign Affairs and Cooperation, Spain ■ Ministry of Foreign Affairs of Denmark ■ Ministry of Foreign Affairs of the Netherlands ■ Ministry of Science & Technology, Government of India ■ National Institute of Allergy and Infectious Diseases ■ Norwegian Royal Ministry of Foreign Affairs ■ Robert Wood Johnson Foundation ■ The Starr Foundation ■ U.K. Department for International Development ■ The U.S. President's Emergency Plan for AIDS Relief through the U.S. Agency for International Development ■ The World Bank through its Development Grant Facility



IAVI gratefully acknowledges the generous support provided by the following major donors



This publication is made possible with support from:

Founded in 1995, AVAC is an international, non-profit organization that uses education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of biomedical HIV prevention options as part of a comprehensive response to the pandemic. AVAC is based in the US, and focuses on issues and priorities in countries where prevention research and implementation are ongoing. Specifically, we seek to deliver proven HIV prevention tools for immediate impact; demonstrate and roll out new HIV prevention options; and develop long-term solutions needed to end the epidemic.



AIDS Vaccines by the Numbers

Trials, discoveries, money and more




FEBRUARY 2015
avac.org

AIDS Vaccines by the Numbers


Trials, discoveries, money and more

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials — even those with disappointing results — and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

THE NUMBER OF AIDS VACCINE TRIALS CURRENTLY UNDERWAY (2014)




VACCINE CONCEPTS CURRENTLY IN CLINICAL TRIALS (2014)



Data from www.avac.org/pxrd


NUMBER OF BROADLY NEUTRALIZING ANTIBODIES DISCOVERED



Data from the Broadly Neutralizing Antibodies Electronic Resource, (bnAber.org)


TIME TO DEVELOP A VACCINE

Duration between discovery of microbiologic cause of selected infectious diseases and development of a vaccine





Source: AVAC AIDS Vaccine Handbook

AIDS VACCINE CLINICAL TRIAL PARTICIPANTS BY REGION (2012)




2012 data from HIV Vaccines & Microbicides Resource Tracking Working Group

GLOBAL INVESTMENT IN R&D (2012)



2012 data from HIV Vaccines & Microbicides Resource Tracking Working Group, Policy Cures G-FINDER and Battelle Global R&D Funding Forecast

NEW HIV INFECTIONS BY REGION (2012)



Adapted from 2012 data from UNAIDS 2012 By the Numbers

EPIDEMICS SUCCESSFULLY COMBATED WITH VACCINES (CASES 1980 – TODAY)



Data from the World Health Organization, estimated cases

THE WORLD NEEDS AN AIDS VACCINE

